Janssen Ad26. RSV. preF Vaccine Description for 2022
Janssen Ad26. RSV. preF Vaccine uses its innovative vaccine technology platform®. This technology is based on the development and production of adenoviral vectors (for transfer of hereditary material) which can activate the immune system to stimulate immunity against the virus.
According to the CDC, Respiratory Syncytial Virus Infection (RSV) was discovered in 1956 and has since been recognized as one of the most common causes of childhood illness. It causes annual outbreaks of respiratory illnesses in all age groups. In most regions of the United States, RSV usually circulates during fall, winter, and spring, but the timing and severity of RSV season in a given community can vary from year to year.
Although most children will be infected by RSV within the first year of life, adults are also susceptible to the virus. Usually, the illness is mild however some adults may have severe symptoms consistent with a lower respiratory tract infection, such as pneumonia.
Janssen Ad26. RSV. preF Vaccine has been tested in several clinical trials with older adults. Positive results from the Phase 2b CYPRESS study have led to the initiation of a Phase 3 EVERGREEN study.
Janssen Ad26. RSV. preF Vaccine Indication
Janssen Ad26. RSV. preF Vaccine candidate is indicated to prevent illness from RSV.
Janssen Ad26. RSV. preF Vaccine News 2021- 2022
September 29, 2021 - "Positive data from our first RSV vaccine efficacy study and the initiation of the Phase 3 EVERGREEN study are crucial milestones in the clinical development of our investigational RSV adult vaccine, which has the potential to safely and effectively prevent lower respiratory tract disease caused by RSV in older adults," says Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC.
January 5, 2021 - The Journal of Infectious Diseases published the results of a Phase 2 study. Ad26.RSV.preF demonstrated protection from RSV infection through immunization in a human challenge model, and therefore could potentially protect against natural RSV infection and disease.
Janssen Ad26. RSV. preF Vaccine Clinical Trials
Janssen Ad26. RSV. preF Vaccine has been studied in many clinical trials.
A phase 3 trial is in the process of recruiting 1,113 adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.